[Top][All Lists]

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

Handpicked for growth

From: Candace Holman
Subject: Handpicked for growth
Date: Mon, 29 Aug 2005 00:51:25 -0500


Issue: 104805
August 2005
Worldwide Biotech & Pharmaceutical Co
Rapid Growth Alert
Symbol: WWBP
52 Week Range 2.00 - 11.00
Shares Float: 25,000,000
Current Price: $3.73
12 Mo.Target Price $22.00
 Growth Rating High

Breaking News Alerts!

0.73 (24.33%) On Friday Alone

Get In While You Still Can!

Worldwide Biotech & Pharmaceutical Obtains the China Patent Golden Medal For Its 'Intact Hepatitis C Virus (HCV) and Method for Culturing HCV in Vitro by Cell Culture'

Thursday August 25, 9:00 am ET

Marks the Highest Award Over the Past 10 Years in the Biomedical Sciences Industry in China

XI'AN, China, Aug. 25 /Xinhua-PRNewswire/ -- Worldwide Biotech & Pharmaceutical Company (OTC Bulletin Board: WWBP - News; ''WWBP'') has obtained the China Patent Golden Medal for ''the Intact Hepatitis C Virus (HCV) and Method for Culturing HCV in Vitro by Cell Culture.''

The project ''The Intact Hepatitis C Virus (HCV) and Method for Culturing HCV in vitro by Cell Culture'' was awarded the Chinese Patent by China Patent Bureau on October 23rd, 2002. The patent was then awarded the prestigious China Patent Golden Medal (Chinese Patent No. 01124001.6) in the 8th China Patent Assessment organized by both General World Intellectual Property Organization (WIPO) and the China Patent Office. Importantly, this patent was recognized by the World Intellectual Property Organization (WIPO), issued as an outstanding Chinese Patented Invention, and was the highest award issued for achievements in the biomedical sciences industry over the past 10 years in China.

''We are highly encouraged with our patent which is recognized by the WIPO and it is such a great achievement for the whole company. It's a great milestone,'' said WenXia Guo, CEO and President of WWBP, ''the success of this patented invention leads our company to a worldwide market, we will continue our development and research of new inventions and bring health to every customer.''

About World Intellectual Property Organization (WIPO)

The World Intellectual Property Organization (WIPO) is an international organization dedicated to promoting the use and protection of works of the human spirit. These works -- intellectual property -- are expanding the bounds of science and technology and enriching the world of the arts. Through its work, WIPO plays an important role in enhancing the quality and enjoyment of life, as well as creating real wealth for nations. With headquarters in Geneva, Switzerland, WIPO is one of the 16 specialized agencies of the United Nations system of organizations. It administers 23 international treaties dealing with different aspects of intellectual property protection.

About Worldwide Biotech & Pharmaceutical Company

Worldwide Biotech & Pharmaceutical Co. (''WWBP'') is a hi-tech biotech company with top-ranking pharmaceutical R&D abilities, Good Manufacturing Practices (GMP) licensed manufacturing facilities and a well-established marketing network in China and Southeast Asia. The product range of WWBP covers Hepatitis C Virus (HCV) products, diagnostic medicines and Over-The-Counter (OTC) drugs. WWBP currently possesses 35,940 square meters of land and 5,359 square meters of GMP standard facilities. With strong pharmaceutical R&D abilities especially in the HCV field, WWBP has been known as the first biotech company in the world to hold the technology of culturing intact HCV in vitro by cell culture.

WWBP has achieved a GMP production scale level of 10,000 ml for concentrated HCV material and 10 grams HCV antigen per month, which is expected to bring WWBP considerable gross sale revenue each year and greatly strengthen the company's R&D on anti-HCV drug screen and HCV human vaccine. WWBP had successfully reached two Memoriam of Understanding of Merger Agreements with pharmaceutical companies in China, all of which have scalable production and well-established sales networks, and the acquiring is expected to be finished before the end of September 2005. The acquisitions will strengthen WWBP's R&D abilities and production scale, as well as extend its marketing network throughout China and Southeast Asia. WWBP has been working closely with pharmaceutical research institutes, and has established connections with both central & local governments.

Worldwide Biotech and Pharmaceutical Company, by and through its wholly owned subsidiary, Yangling Daiying Biotech and Pharmaceutical Group Co., Ltd., formerly Yangling Daiying Biotech Engineering Co., Ltd. (Daiying), a company incorporated on November 2001 in Shaanxi Province, China, has, effective on July 12, 2005, entered into an investment contract with Xian Jinyou Investment Management Co., Ltd. (Jinyou), for the purposes of forming a new company to be formed as a limited liability company pursuant to the laws and regulations of China, said company to be known as Shaanxi Daiying Medicine Distribution Co., Ltd.
Stock-based compensation expense increased to $2,837,946 for the six months ended June 30, 2005 from $0 for the six months ended June 30, 2004. The increase in stock-based compensation expense was attributable to the amortization of deferred compensation related to previously granted stock warrants and the granting of common stock to consultants for business development services rendered. As of June 30, 2005, we had deferred consulting expense of $1,052,000 that will be amortized into operations in the future that will have a negative effect on our operations. We expect to incur similar stock-based compensation and consulting expense in the future.
Pursuant to the Investment Agreement, both Daiying and Jinyou will invest a total of approximately $600,000.00 U.S. Dollars of which Daiying will investment $445,000.00 for 90 percent of Shaanxi Daiying and Jinyou will invest approximately $155,000.00 for 10 percent for Shaanxi Daiying. The companys anticipated purpose is the wholesale distribution of traditional Chinese medicine, including Chinese medicine drink tablets, synthetic medicine, antibiotics, biotech medicine and biotech reagents; wholesale of Class II medical devices, Class III medical devices, including but not limited to, medical sewing materials and bond, medical high molecular materials and products, and disposable sterile medical devices. Investors will not be required to invest until three (3) months after applying for the companys business name, at the business administrations office in China, and at said time said funds shall be funded.

Management's Discussion and Analysis of Financial Condition and Results of Operation

reply via email to

[Prev in Thread] Current Thread [Next in Thread]